Logo image of LITS

LITE STRATEGY INC (LITS) Stock Fundamental Analysis

USA - NASDAQ:LITS - US55279B3015 - Common Stock

2.71 USD
+0.1 (+3.83%)
Last: 9/18/2025, 5:27:35 PM
2.82 USD
+0.11 (+4.06%)
After Hours: 9/18/2025, 5:27:35 PM
Fundamental Rating

4

LITS gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 540 industry peers in the Biotechnology industry. While LITS has a great health rating, there are worries on its profitability. LITS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year LITS was profitable.
LITS had a negative operating cash flow in the past year.
In the past 5 years LITS reported 4 times negative net income.
In the past 5 years LITS reported 4 times negative operating cash flow.
LITS Yearly Net Income VS EBIT VS OCF VS FCFLITS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -152.38%, LITS is doing worse than 85.93% of the companies in the same industry.
With a Return On Equity value of -162.03%, LITS is not doing good in the industry: 63.52% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -152.38%
ROE -162.03%
ROIC N/A
ROA(3y)-4.67%
ROA(5y)-12.05%
ROE(3y)-59.83%
ROE(5y)-64.83%
ROIC(3y)N/A
ROIC(5y)N/A
LITS Yearly ROA, ROE, ROICLITS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

LITS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
LITS Yearly Profit, Operating, Gross MarginsLITS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

9

2. Health

2.1 Basic Checks

LITS does not have a ROIC to compare to the WACC, probably because it is not profitable.
LITS has less shares outstanding than it did 1 year ago.
LITS has more shares outstanding than it did 5 years ago.
There is no outstanding debt for LITS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
LITS Yearly Shares OutstandingLITS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
LITS Yearly Total Debt VS Total AssetsLITS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 12.02 indicates that LITS is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 12.02, LITS belongs to the top of the industry, outperforming 87.96% of the companies in the same industry.
There is no outstanding debt for LITS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 12.02
ROIC/WACCN/A
WACC9.57%
LITS Yearly LT Debt VS Equity VS FCFLITS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 16.78 indicates that LITS has no problem at all paying its short term obligations.
LITS's Current ratio of 16.78 is amongst the best of the industry. LITS outperforms 92.22% of its industry peers.
LITS has a Quick Ratio of 16.78. This indicates that LITS is financially healthy and has no problem in meeting its short term obligations.
LITS has a Quick ratio of 16.78. This is amongst the best in the industry. LITS outperforms 92.22% of its industry peers.
Industry RankSector Rank
Current Ratio 16.78
Quick Ratio 16.78
LITS Yearly Current Assets VS Current LiabilitesLITS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

3

3. Growth

3.1 Past

LITS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 157.67%, which is quite impressive.
LITS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
Measured over the past years, LITS shows a very strong growth in Revenue. The Revenue has been growing by 67.72% on average per year.
EPS 1Y (TTM)157.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.81%
Revenue 1Y (TTM)-100%
Revenue growth 3Y23.34%
Revenue growth 5Y67.72%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, LITS will show a very negative growth in Earnings Per Share. The EPS will decrease by -37.44% on average per year.
Based on estimates for the next years, LITS will show a very negative growth in Revenue. The Revenue will decrease by -27.39% on average per year.
EPS Next Y-339.91%
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y-38.12%
Revenue Next 3Y-27.39%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
LITS Yearly Revenue VS EstimatesLITS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 20M 40M 60M
LITS Yearly EPS VS EstimatesLITS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -5 -10 -15 -20 -25

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 1.01, the valuation of LITS can be described as very cheap.
Based on the Price/Earnings ratio, LITS is valued cheaper than 99.63% of the companies in the same industry.
LITS is valuated cheaply when we compare the Price/Earnings ratio to 27.41, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for LITS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 1.01
Fwd PE N/A
LITS Price Earnings VS Forward Price EarningsLITS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
LITS Per share dataLITS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2

4.3 Compensation for Growth

A cheap valuation may be justified as LITS's earnings are expected to decrease with -37.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%

More info and screens

0

5. Dividend

5.1 Amount

LITS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

LITE STRATEGY INC

NASDAQ:LITS (9/18/2025, 5:27:35 PM)

After market: 2.82 +0.11 (+4.06%)

2.71

+0.1 (+3.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-17 2025-09-17/amc
Earnings (Next)11-10 2025-11-10
Inst Owners9.02%
Inst Owner ChangeN/A
Ins Owners1.24%
Ins Owner ChangeN/A
Market Cap89.00M
Analysts43.33
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend1.75
Dividend Growth(5Y)N/A
DP0%
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 1.01
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.55
P/tB 4.55
EV/EBITDA N/A
EPS(TTM)2.67
EY98.52%
EPS(NY)-3.78
Fwd EYN/A
FCF(TTM)-1.11
FCFYN/A
OCF(TTM)-1.11
OCFYN/A
SpS0
BVpS0.6
TBVpS0.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -152.38%
ROE -162.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-4.67%
ROA(5y)-12.05%
ROE(3y)-59.83%
ROE(5y)-64.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 16.78
Quick Ratio 16.78
Altman-Z 12.02
F-Score2
WACC9.57%
ROIC/WACCN/A
Cap/Depr(3y)52.51%
Cap/Depr(5y)242.29%
Cap/Sales(3y)0.42%
Cap/Sales(5y)1.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)157.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%71.81%
EPS Next Y-339.91%
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%
EPS Next 5YN/A
Revenue 1Y (TTM)-100%
Revenue growth 3Y23.34%
Revenue growth 5Y67.72%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-38.12%
Revenue Next 3Y-27.39%
Revenue Next 5YN/A
EBIT growth 1Y-200.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y36.17%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y35.82%
OCF growth 3YN/A
OCF growth 5YN/A